pour la recherche uniquement

Deferoxamine mesylate Ferroptosis inhibiteur

Réf. CatalogueS5742

Le Deferoxamine mesylate est le sel mésylate de Deferoxamine, qui forme des complexes de fer et est utilisé comme agent chélateur. Le Deferoxamine est un inhibiteur de la ferroptosis qui stabilise l'expression de HIF-1α et améliore la transactivité de HIF-1α dans les états hypoxiques et hyperglycémiques in vitro. Le Deferoxamine diminue le dépôt de bêta-amyloïde (Aβ) et induit l'autophagy.Veuillez ne pas préparer de solutions mères avec du sérum physiologique ou du PBS, car une précipitation peut se produire.
Deferoxamine mesylate Ferroptosis inhibiteur Chemical Structure

Structure chimique

Poids moléculaire: 656.79

Aller à

Contrôle Qualité

Lot : Pureté : 99.74%
99.74

Produits souvent utilisés avec Deferoxamine mesylate

Z-VAD-FMK

It can reverse the cell proliferative activity of granulosa cells in EMFF but not Z-VAD-FMK.

Ferrostatin-1 (Fer-1)

It and Ferrostatin-1 can reverse the cell proliferative activity of granulosa cells in EMFF.

SRS11-92

It can reverse the cell proliferative activity of granulosa cells in EMFF but not Necrostatin-1.

Culture cellulaire, traitement et concentration de travail

Lignées cellulaires Type dessai Concentration Temps dincubation Formulation Description de lactivité PMID
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM. 17602603
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM. 19601577
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM. 19216562
A549 Antiproliferative assay 72 hrs Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM. 22861499
SK-N-MC Antiproliferative assay 96 hrs Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM. 17064069
MDCK Toxicity assay Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM. 20041672
SK-N-MC Cytotoxicity assay 72 hrs Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM. 20303768
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM. 22861499
DMS53 Antiproliferative assay 72 hrs Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM. 22861499
SK-MN-C Antiproliferative assay Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM. 18159922
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM. 22858101
SK-N-MC Antiproliferative assay Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM. 17963372
SK-N-MC Toxicity assay Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM. 20041672
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM. 28841514
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. 21055950
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. 22172311
U2OS Function assay 30 mins Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM. 22172704
HL60 Cytotoxicity assay Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM. 23266185
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM. 23312948
SK-N-MC Antiproliferative assay Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM. 19601577
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM. 21846118
SK-N-MC Cytotoxicity assay 72 hrs Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM. 23276209
K562 Cytotoxicity assay Cytotoxicity against human K562 cells, GI50 = 33.1 μM. 23266185
HT29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM. 18345610
HT-29 Cell cycle assay 10 uM 24 hrs Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs 20353152
HT-29 Cell cycle assay 5 uM 24 hrs Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs 20353152
HCT116 Function assay 24 hrs Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3 24900837
HeLa Bacteriostatic assay >100 uM 1 hr Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy 25027937
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay 28285915
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay 28285915
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay 28285915
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay 28285915
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
Cliquez pour voir plus de données expérimentales sur la lignée cellulaire

Informations chimiques, stockage et stabilité

Poids moléculaire 656.79 Formule

C26H52N6O11S

Stockage (À compter de la date de réception) 3 years -20°C powder
N° CAS 138-14-7 -- Stockage des solutions mères

Solubilité

In vitro
Lot:

DMSO : 100 mg/mL (152.25 mM)
(Le DMSO contaminé par lhumidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Water : 100 mg/mL

Ethanol : Insoluble

Calculateur de molarité

Masse Concentration Volume Poids moléculaire
Calculateur de dilution Calculateur de poids moléculaire

In vivo
Lot:

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)

mg/kg g μL

Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.

Note : 1. Veuillez vous assurer que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue, lors de lajout précédent, est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.

Mécanisme daction

Targets/IC50/Ki
HIF-1α
Beta Amyloid
Ferroptosis
In vitro

Le Deferoxamine mesylate, le chélateur de fer et inhibiteur de la ferroptosis, sauve la mort des neutrophiles induite par le sérum du lupus érythémateux systémique (LES), suggérant que la ferroptosis pourrait être la principale forme de mort des neutrophiles dans le LES.

In vivo

Le Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) est le sel mésylate de Deferoxamine, qui forme des complexes de fer et est utilisé comme agent chélateur.

Références
  • [4] https://pubmed.ncbi.nlm.nih.gov/2538902/

Support technique

Instructions de manipulation

Tel: +1-832-582-8158 Ext:3

Si vous avez dautres questions, veuillez laisser un message.

Veuillez entrer votre nom.
Veuillez entrer votre courriel. Veuillez entrer une adresse courriel valide.
Veuillez nous écrire quelque chose.